| Company Name: | AtheroGenics, Incorporated | | Ticker Symbol: | AGIX | | | WWW Address: | www.AtheroGenics.com |
| CEO: | Dr. Russell M. Medford, M.D., Ph.D. | | No. of Employees: | 57 |
| Common Issue Type: | CS | | Business Description: | A pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease.
|
| | | Industry Information: | DRUGS - Drug Manufacturers - Other [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 0.07 |  0.0 | - | - | | 0.09 | 0.05 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 2.8 | 39.5 | 0.89 | -1.25 | 0.00 | 0.0 | 0.0 | 1.72 - 0.05 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 0.07 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 2.8 | mil |
| Latest Shares Outstanding | 39.5 | mil |
| Earnings pS (EPS) | -1.25 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 917,137 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 38.2 | mil |
| Float as % of Shares Outstanding | 96.6 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 118.10 | % |
| Research & Devlopment (R&D) as % of Revenue | 455.80 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.1 | % |
| Return on Assets (ROA) | -82.7 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -185.0 | % |
| Current Ratio | 1.7 | |
| Leverage Ratio (Assets/Equity) | 0.0 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 786.0 | % |
| Working Capital pS | 0.68 | $ |
| Cash pS | 1.62 | $ |
| Book-Value pS | 0.00 | $ |
| Tangible Book-Value pS | -5.62 | $ |
| Cash Flow pS | -1.34 | $ |
| Free Cash Flow pS | -1.09 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 0.00 | |
| Price/Tangible Book Ratio | -0.01 | |
| Price/Cash Flow | -0.1 | |
| Price/Free Cash Flow | -0.1 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -12.5 | 78 | 13,093 | 18,485 |
| 4 Weeks | 0.43 | 0.05 | 0.26 | -73.1 | 34 | 10,206 | 163,288 |
| 13 Weeks | 1.08 | 0.05 | 0.67 | -89.6 | 13 | 9,298 | 557,905 |
| 26 Weeks | 1.08 | 0.05 | 0.72 | -90.3 | 13 | 5,770 | 709,717 |
| 52 Weeks | 1.72 | 0.05 | 1.68 | -95.8 | 6 | 7,283 | 1,798,956 |
| YTD | 1.25 | 0.05 | - | -81.6 | 27 | 6,778 | 1,341,970 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 0.10 | 0.20 | 0.50 | 0.61 | 0.59 | 0.89 | 0.38 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.00 | 0.0 | 0.00 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 6.19 | NA | 102.53 |
| R&D | 13.34 | NA | -3.09 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -100.0 | -100.0 | 65.0 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | -0.26 | -0.20 | 0.46 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 48.70 |
| Current Ratio | 2.1 |
| Quick Ratio (Acid Test) | 2.1 |
| Liquidity Ratio (Cash) | 1.99 |
| Receivables Turnover | 10.3 |
| Average Collection Period | 35 |
| Working Capital/Equity | -25.7 |
| Working Capital pS | 1.27 |
| Cash-Flow pS | -1.82 |
| Free Cash-Flow pS | -1.49 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | -0.81 |
| Financial Leverage Ratio (Assets/Equity) | 0.0 |
| Debt Ratio | 289.6 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 445.8 |
| LT Debt/Total Liabilities | 84.4 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 19.67 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 0.13 |
| Tobin's Q Ratio | 0.03 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -3.68 |
| Enterprise Value (EV)/Free Cash Flow | 0.64 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | -0.01 |
| Price/Book Ratio - LTM | 0.00 |
| Price/Cash Flow Ratio | -0.1 |
| Price/Free Cash Flow Ratio - LTM | -0.1 |
| Price/Sales Ratio | 0.26 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 6.38 |
| Current Liabilities pS | 1.18 |
| Tangible Book Value pS - LTM | -5.62 |
| Book Value pS - LTM | 0.00 |
| Capital Invested pS | 1.43 |
| Cash pS - LTM | 1.62 |
| Cash Flow pS - LTM | -1.34 |
| Free Cash Flow pS - LTM | -1.09 |
| Earnings pS (EPS) | -1.25 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -112.80 |
| Free Cash Flow Margin 5YEAR AVG | -43.10 |
| Net Profit Margin | -94.6 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | -0.27 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.92 |
| Return on Capital Invested (ROCI) | -87.4 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -56.8 |
| Assets Productivity | 0.40 |
| Return on Assets (ROA) | -48.0 |
| Return on Assets (ROA) - 5YEAR AVRG. | -46.5 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 55.7 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | -94.6 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 21 |
| Revenue per Employee | 917,137 |
| Net Income per Employee | -867,870 |
| Average Collection Period | 21 |
| Receivables Turnover | 10.3 |
| Day's Inventory Turnover Ratio | |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 70.30 |
| Assets/Revenue | 2.50 |
| Net Working Capital Turnover | 1.04 |
| Fixed Assets Turnover | 8.25 |
| Total Assets Turnover | 0.4 |
| Revenue per $ Cash | 0.70 |
| Revenue per $ Plant | 22.14 |
| Revenue per $ Common Equity | -0.27 |
| Revenue per $ Capital Invested | 0.92 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 26.7 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 57.7 |
| Research & Devlopment (R&D) as % of Revenue | 139.1 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 139.1 |
|
|  
|
| |
 |  |
